問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


National Taiwan University Hospital (在職)

Division of Urology

Division of Pediatrics

Division of Hematology & Oncology

更新時間：2023-09-19

黃國皓-, -
  • Principal Investigator
  • Clinical Trial Experience (year) 17 years 9 個月

Recruiting Trial

25Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

黃國皓

List

64Cases

2007-05-01 - 2009-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-09-30 - 2013-09-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2009-12-01 - 2013-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2016-02-01 - 2020-07-31

Phase III

A Phase 3 Randomized, Double-blind, Multi-center Study of Adjuvant Nivolumab versus Placebo in Subjects with High Risk Invasive Urothelial Carcinoma

  • Condition/Disease

    高風險侵襲性泌尿上皮細胞癌

  • Test Drug

    Nivolumab

Participate Sites
4Sites

Terminated2Sites

Study ended1Sites

2017-08-01 - 2020-12-31

Phase III

HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men with Advanced Prostate Cancer

  • Condition/Disease

    Advanced Prostate Cancer

  • Test Drug

    Relugolix 120 mg

Participate Sites
5Sites

Terminated4Sites

黃書彬
Kaohsiung Municipal Gangshan Hospital

未分科

2011-06-01 - 2015-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2010-09-30 - 2013-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2010-12-01 - 2012-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
10Sites

Terminated10Sites

2010-09-30 - 2014-08-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated9Sites

2019-06-01 - 2024-07-31

Phase III

A Phase 3, Randomized, Double-blind Study to Compare the Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with Lenvatinib (E7080/MK-7902) Versus Pembrolizumab and Placebo as First Line Treatment for Locally Advanced or Metastatic Urothelial Carcinoma in Cisplatin-ineligible Participants Whose Tumors Express PD-L1, and in Participants Ineligible for Any Platinum-containing Chemotherapy Regardless of PD-L1 Expression (LEAP-011)

  • Condition/Disease

    Locally Advanced or Metastatic Urothelial Carcinoma

  • Test Drug

    Lenvatinib Pembrolizumab

Participate Sites
7Sites

Recruiting7Sites

吳文正
Kaohsiung Medical Univeristy Chung-Ho Memorial Hospital

Division of Urology

1 3 4 5 6 7
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB